论文部分内容阅读
目的探讨米卡芬净治疗儿童恶性血液病并侵袭性肺部真菌感染的疗效及安全性。方法选取柘城县人民医院血液/肿瘤病区治疗恶性血液病合并肺部真菌感染患儿51例,随机分为两组,分别给予米卡芬净与伏立康唑治疗,比较两组的治疗有效率、痊愈率和不良反应发生率。结果两组患儿在有效率和痊愈率方面比较差异无统计学意义(P>0.05),但在不良反应发生率方面,米卡芬净组患儿低于伏立康唑组患儿,差异有统计学意义(P<0.05)。结论米卡芬净与伏立康唑对儿童恶性血液病侵袭性肺部真菌感染均具有良好的疗效,但米卡芬净具有更好的安全性。
Objective To investigate the efficacy and safety of micafungin in the treatment of children with hematologic malignancies and invasive pulmonary fungal infections. Methods Totally 51 children with malignant hematological disease and pulmonary fungal infection were selected from Tancheng County People’s Hospital Blood / Cancer Disease Area and randomly divided into two groups, treated with micafungin and voriconazole, respectively. The treatment efficiency, The cure rate and the incidence of adverse reactions. Results There was no significant difference between the two groups in the effective rate and the cure rate (P> 0.05). However, in the incidence of adverse reactions, the children in the micafungin group were lower than those in the voriconazole group, the difference was statistically significant Significance (P <0.05). Conclusions Both micafungin and voriconazole have a good effect on invasive pulmonary fungal infection in children with hematologic malignancies, but micafungin has better safety.